Predictors of Mechanical Ventilation in Guillain-Barré Syndrome with Axonal Subtypes.

BACKGROUND: The early clinical predictors of respiratory failure in Latin Americans with Guillain-Barré syndrome (GBS) have scarcely been studied. This is of particular importance since Latin America has a high frequency of axonal GBS variants that may imply a worse prognosis. METHODS: We studied 86 Mexican patients with GBS admitted to the Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, a referral center of Mexico City, to describe predictors of invasive mechanical ventilation (IMV). RESULTS: The median age was 40 years (interquartile range: 26-53.5), with 60.5% men (male-to-female ratio: 1.53). Most patients (65%) had an infectious antecedent (40.6% gastrointestinal). At admission, 38% of patients had a Medical Research Council (MRC) sum score <30. Axonal subtypes predominated (60.5%), with acute motor axonal neuropathy being the most prevalent (34.9%), followed by acute inflammatory demyelinating polyneuropathy (32.6%), acute motor sensory axonal neuropathy (AMSAN) (25.6%), and Fisher syndrome (7%). Notably, 15.1% had onset in upper limbs, 75.6% dysautonomia, and 73.3% pain. In all, 86% received either IVIg (9.3%) or plasma exchange (74.4%). IMV was required in 39.5% patients (72.7% in AMSAN). A multivariate model without including published prognostic scores yielded the time since onset to admission <15 days, axonal variants, MRC sum score <30, and bulbar weakness as independent predictors of IMV. The model including grading scales yielded lower limbs onset, Erasmus GBS respiratory insufficiency score (EGRIS) >4, and dysautonomia as predictors. CONCLUSION: These results suggest that EGRIS is a good prognosticator of IMV in GBS patients with a predominance of axonal electrophysiological subtypes, but other early clinical data should also be considered.

Posterior reversible encephalopathy syndrome during convalescence from COVID-19.

Background and aim: With an ever-increasing population of patients recovering form severe coronavirus disease 2019 (COVID-19), recognizing long-standing and delayed neurologic manifestations is crucial. Here, we present a patient developing posterior reversible encephalopathy syndrome (PRES) in the convalescence form severe coronavirus disease 2019 (COVID-19).Case presentation: A 61-year-old woman with severe (COVID-19) confirmed by nasopharyngeal real-time reverse transcription-polymerase chain reaction (RT-PCR) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) required invasive mechanical ventilation 24-hours after admission. During her intensive care unit stay, she developed transient acute kidney injury and septic shock. She was extubated after 22 days. On day 25, she developed generalized tonic-clonic seizures. Magnetic resonance imaging (MRI) of the brain showed bilateral subcortical lesions on the parietal and occipital lobes and multiple micro-and macro-bleeds, consistent with PRES. At this point, RT-PCR for SARS-CoV-2 in a respiratory specimen and cerebrospinal fluid was negative. She was discharged home 35 days after admission on oral levetiracetam. Control MRI five months after discharge showed bilateral focal gliosis. On follow-up, she remains seizure-free on levetiracetam.Conclusions: PRES has been observed before as a neurological manifestation of acute COVID-19; to our knowledge, this is the first PRES case occurring in a hospitalized patient already recovered from COVID-19. A persistent proinflammatory/prothrombotic state triggered by SARS-CoV-2 infection may lead to long-standing endothelial dysfunction, resulting in delayed PRES in patients recovering from COVID-19. With a rapid and exponential increase in survivors of acute COVID-19, clinicians should be aware of delayed (post-acute) neurological damage, including PRES.

Incidence of Guillain-Barré syndrome following SARS-CoV-2 immunization: Analysis of a nationwide registry of recipients of 81 million doses of seven vaccines.

BACKGROUND AND PURPOSE: Information on Guillain-Barré syndrome (GBS) as an adverse event following immunization (AEFI) against SARS-CoV-2 remains scarce. We aimed to report GBS incidence as an AEFI among adult (≥18 years) recipients of 81,842,426 doses of seven anti-SARS-CoV-2 vaccines between December 24, 2020, and October 29, 2021, in Mexico. METHODS: Cases were retrospectively collected through passive epidemiological surveillance. The overall observed incidence was calculated according to the total number of administered doses. Vaccines were analyzed individually and by vector as mRNA-based (mRNA-1273 and BNT162b2), adenovirus-vectored (ChAdOx1 nCov-19, rAd26-rAd5, Ad5-nCoV, and Ad26.COV2-S), and inactivated whole-virion-vectored (CoronaVac) vaccines. RESULTS: We identified 97 patients (52 males [53.6%]; median [interquartile range] age 44 [33-60] years), for an overall observed incidence of 1.19/1,000,000 doses (95% confidence interval [CI] 0.97-1.45), with incidence higher among Ad26.COV2-S (3.86/1,000,000 doses, 95% CI 1.50-9.93) and BNT162b2 recipients (1.92/1,00,000 doses, 95% CI 1.36-2.71). The interval (interquartile range) from vaccination to GBS symptom onset was 10 (3-17) days. Preceding diarrhea was reported in 21 patients (21.6%) and mild COVID-19 in four more (4.1%). Only 18 patients were tested for Campylobacter jejuni (positive in 16 [88.9%]). Electrophysiological examinations were performed in 76 patients (78.4%; axonal in 46 [60.5%] and demyelinating in 25 [32.8%]); variants were similar across the platforms. On admission, 91.8% had a GBS disability score ≥3. Seventy-five patients (77.3%) received intravenous immunoglobulin, received seven plasma exchange (7.2%), and 15 (15.5%) were treated conservatively. Ten patients (10.3%) died, and 79.1% of survivors were unable to walk independently. CONCLUSIONS: Guillain-Barré syndrome was an extremely infrequent AEFI against SARS-CoV-2. The protection provided by these vaccines outweighs the risk of developing GBS.

Guillain-Barré syndrome is infrequent among recipients of the BNT162b2 mRNA COVID-19 vaccine.

Vaccines are the most effective strategy to mitigate the global impact of COVID-19. However, vaccine hesitancy is common, particularly among minorities. Guillain-Barré syndrome (GBS) is the most common autoimmune illness of the peripheral nervous system, occurring at an incidence of 1.1/100,000 worldwide. A causal link between mRNA vaccines and GBS has not been previously evaluated. We analyzed a cohort of 3,890,250 Hispanic/Latinx recipients of the BNT162b2 mRNA vaccine (613,780 of whom had already received both doses) for incident GBS occurring within 30 days from vaccine administration. Seven cases of GBS were detected among first-dose recipients, for an observed incidence of 0.18/100,000 administered doses during the prespecified timeframe of 30 days. No cases were reported after second-dose administration. Our data suggest that, among recipients of the BNT162b2 mRNA vaccine, GBS may occur at the expected community-based rate; however, this should be taken with caution as the current incidence of GBS among the unvaccinated population against COVID-19 is still undetermined. We hope that this preliminary data will increase the public perception of safety toward mRNA-based vaccines and reduce vaccine hesitancy.

Neurologic adverse events among 704,003 first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine in Mexico: A nationwide descriptive study.

mRNA vaccines against SARS-CoV-2 are remarkably effective. Limited information exists about the incidence of adverse events following immunization (AEFI) with their use. We conducted a prospective observational study including data from 704,003 first-doses recipients; 6536 AEFI were reported, of whom 65.1% had at least one neurologic AEFI (non-serious 99.6%). Thirty-three serious events were reported; 17 (51.5%) were neurologic (observed frequency, 2.4/100,000 doses). At the time of writing this report, 16/17 cases had been discharged without deaths. Our data suggest that the BNT162b2 mRNA COVID-19 vaccine is safe; its individual and societal benefits outweigh the low percentage of serious neurologic AEFI. This information should help to dissipate hesitancy towards this new vaccine platform.

Characteristics and predictors for silent hypoxemia in a cohort of hospitalized COVID-19 patients.

BACKGROUND: An intriguing feature recently unveiled in some COVID-19 patients is the "silent hypoxemia" phenomenon, which refers to the discrepancy of subjective well-being sensation while suffering hypoxia, manifested as the absence of dyspnea. OBJECTIVE: To describe the clinical characteristics and predictors of silent hypoxemia in hospitalized COVID-19 patients. METHODS: We conducted a prospective cohort study including consecutive hospitalized adult (≥ 18 years) patients with confirmed COVID-19 presenting to the emergency department with oxygen saturation (SpO2) ≤ 80% on room air from March 15 to June 30, 2020. We analyzed the characteristics, disease severity, and in-hospital outcomes of patients presenting with dyspnea and those without dyspnea (silent hypoxemia). RESULTS: We studied 470 cases (64.4% men; median age 55 years, interquartile range 46-64). There were 447 (95.1%) patients with dyspnea and 23 (4.9%) with silent hypoxemia. The demographic and clinical characteristics, comorbidities, laboratory and imaging findings, disease severity, and outcomes were similar between groups. Higher breathing and heart rates correlated significantly with lower SpO2 in patients with dyspnea but not in those with silent hypoxemia. Independent predictors of silent hypoxemia were the presence of new-onset headache (OR 2.919, 95% CI 1.101-7.742; P = 0.031) and presenting to the emergency department within the first eight days after symptoms onset (OR 3.183, 95% CI 1.024-9.89; P = 0.045). CONCLUSIONS: Patients with silent hypoxemia sought medical attention earlier and had new-onset headache more often. They were also likely to display lower hemodynamic compensatory responses to hypoxemia, which may underestimate the disease severity.

Neurologic manifestations in hospitalized patients with COVID-19 in Mexico City.

BACKGROUND: The coronavirus disease 2019 (COVID-19) is a systemic entity that frequently implies neurologic features at presentation and complications during the disease course. We aimed to describe the characteristics and predictors for developing in-hospital neurologic manifestations in a large cohort of hospitalized patients with COVID-19 in Mexico City. METHODS: We analyzed records from consecutive adult patients hospitalized from March 15 to June 30, 2020, with moderate to severe COVID-19 confirmed by reverse transcription real-time polymerase chain reaction (rtRT-PCR) for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Neurologic syndromes were actively searched by a standardized structured questionnaire and physical examination, confirmed by neuroimaging, neurophysiology of laboratory analyses, as applicable. RESULTS: We studied 1,072 cases (65% men, mean age 53.2±13 years), 71 patients had pre-existing neurologic diseases (diabetic neuropathy: 17, epilepsy: 15, history of ischemic stroke: eight, migraine: six, multiple sclerosis: one, Parkinson disease: one), and 163 (15.2%) developed a new neurologic complication. Headache (41.7%), myalgia (38.5%), dysgeusia (8%), and anosmia (7%) were the most common neurologic symptoms at hospital presentation. Delirium (13.1%), objective limb weakness (5.1%), and delayed recovery of mental status after sedation withdrawal (2.5%), were the most common new neurologic syndromes. Age, headache at presentation, preexisting neurologic disease, invasive mechanical ventilation, and neutrophil/lymphocyte ratio ≥9 were independent predictors of new in-hospital neurologic complications. CONCLUSIONS: Even after excluding initial clinical features and pre-existing comorbidities, new neurologic complications in hospitalized patients with COVID-19 are frequent and can be predicted from clinical information at hospital admission.

Transient sensory symptoms among first-dose recipients of the BNT162b2 mRNA COVID-19 vaccine: A case-control study.

mRNA-based COVID-19 vaccines are effective; however, persistent vaccine hesitancy is partly due to a misperception of their potential adverse events. Non-specific sensory symptoms (NSSS) following immunization are thought to be mediated by stress-related responses. In this case-control study, we evaluated NSSS from a cohort of 7,812,845 BNT162b2 first-dose recipients, of whom 10,929 reported an adverse event following immunization (AEFI). We found an overall frequency of 3.4% (377 cases) or 4.8 cases per 100,000 doses administered. Anatomically, the arms (61%) and face/neck region (36.2%) were the most commonly affected sites. The control group had significantly higher rates of reactogenicity-associated symptoms, suggesting that NSSS are reactogenicity-independent; in multivariable analysis, healthcare workers reported sensory symptoms less frequently (aOR 0.54; 95% CI 0.40-0.72;p < 0.001). This is the first study describing the topography and associated factors for developing NSSS among BNT162b2 recipients. The benign nature of these symptoms may help dissipate hesitation towards this vaccine.

Heart rate and systolic blood pressure variability on recently diagnosed diabetics.

BACKGROUND: Diabetes affects approximately 250 million people in the world. Cardiovascular autonomic neuropathy is a common complication of diabetes that leads to severe postural hypotension, exercise intolerance, and increased incidence of silent myocardial infarction. OBJECTIVE: To determine the variability of heart rate (HR) and systolic blood pressure (SBP) in recently diagnosed diabetic patients. METHODS: The study included 30 patients with a diagnosis of type 2 diabetes of less than 2 years and 30 healthy controls. We used a Finapres® device to measure during five minutes beat-to-beat HR and blood pressure in three experimental conditions: supine position, standing position, and rhythmic breathing at 0.1 Hz. The results were analyzed in the time and frequency domains. RESULTS: In the HR analysis, statistically significant differences were found in the time domain, specifically on short-term values such as standard deviation of NN intervals (SDNN), root mean square of successive differences (RMSSD), and number of pairs of successive NNs that differ by more than 50 ms (pNN50). In the BP analysis, there were no significant differences, but there was a sympathetic dominance in all three conditions. The baroreflex sensitivity (BRS) decreased in patients with early diabetes compared with healthy subjects during the standing maneuver. CONCLUSIONS: There is a decrease in HR variability in patients with early type 2 diabetes. No changes were observed in the BP analysis in the supine position, but there were changes in BRS with the standing maneuver, probably due to sympathetic hyperactivity.

[The cardiovagal, cardiosympathetic and vasosympathetic arterial baroreflexes and the neural control of short-term blood pressure]. / Los barorreflejos arteriales cardiovagal, cardiosimpatico y vasosimpatico y el control neural de la presion arterial a corto plazo.

INTRODUCTION: The factors that control the blood pressure are punctually regulated to keep it in reference values. These are maintained through autoregulatory mechanisms, humoral, nervous and endothelial-related. The humoral mechanisms are complex and modify the long-term blood pressure, in the other hand, the neurogenic mechanisms, are reflexive and can be observed in beat-to-beat changes of blood pressure. DEVELOPMENT: The nervous cardiovascular reflexes are mediated by high-pressure and low-pressure baroreceptors, as cardiovagal, cardiosympathetic and vasosympathetic. The arterial baroreceptor are stimulated when the blood volume-ejected by the ventricle distend the arterial walls. The neural discharge travels to the autonomic centers in the brain stem and the result is the modification of the heart rate and the vascular smooth muscle tone. This sudden modification is the responsible of the beat-to-beat (short-term) blood pressure variability. CONCLUSION: A review was made on the history of the physiology and experiments of the cardiovagal, cardiosympathetic and vasosympathetic baroreflexes and its influence in the short-term blood pressure variability.

TITLE: Los barorreflejos arteriales cardiovagal, cardiosimpatico y vasosimpatico y el control neural de la presion arterial a corto plazo.Introduccion. Los factores que modulan la presion arterial a corto plazo se encuentran puntualmente regulados para mantenerla dentro de valores de referencia. Esto se logra gracias a la existencia de mecanismos de autorregulacion, tanto humorales como nerviosos. Los mecanismos neurogenicos son reflejos y su resultado se observa en cambios de presion arterial de forma inmediata, latido a latido. Desarrollo. Los reflejos nerviosos cardiovasculares se encuentran mediados por los barorreceptores arteriales, a traves de los efectores cardiovagal, cardiosimpatico y vasosimpatico. El barorreceptor es estimulado cuando el volumen de sangre eyectado por el ventriculo distiende las paredes arteriales del seno carotideo y la aorta proximal y estimula los mecanorreceptores situados en la adventicia de estos vasos. El estimulo aferente viaja hasta el nucleo del haz solitario en el bulbo raquideo y otras areas en el puente donde se integran estos reflejos y la parte eferente genera cambios compensatorios en la frecuencia cardiaca y el tono del musculo liso vascular. Esta modificacion subita es la responsable de la variabilidad de la presion arterial latido a latido (corto plazo). Conclusion. Se realiza una revision sobre la historia, la fisiologia y los experimentos de los barorreflejos cardiovagal, cardiosimpatico y vasosimpatico y su influencia en la variabilidad de la presion arterial a corto plazo.

Does salt addiction exist? / ¿Existe la adicción a la sal?

Abstract: BACKGROUND: Salt consumption activates the brain reward system, inducing cravings and the search for salted food. Its excessive intake is associated with high blood pressure and obesity. The high quantity of salt in processed food is most likely a major cause of the global pandemic of hypertension (HT). OBJECTIVE: To review the current information on the topic of salt addiction and the health consequences this has. METHOD: A search in PubMed, ScienceDirect, and EBSCOhost databases was conducted with the keywords "salt", "salt addiction", and "food addiction". Articles with information relative to the topic of interest were checked, as were references of those articles and historical and culturally complementary information. RESULTS: We described the historical relationship between man and salt, the physiology of salty taste perception, its role in the reward system and the health consequences of a high sodium diet. DISCUSSION AND CONCLUSION: There is physiological and behavioural evidence that some people may develop a true addiction to food. Among these people, salt addiction seems to be of great importance in the development of obesity, HT and other diseases. Sodium is present in high quantities in processed food as salt and monosodium glutamate (MSG), used as flavour enhancers and food preservatives, including in non-salty foods like bread and soft drinks.

Resumen: ANTECEDENTES: El consumo de sal activa el sistema de recompensa cerebral, induciendo el deseo y búsqueda de alimentos salados. Su ingesta excesiva se asocia a presión arterial elevada y obesidad. La gran cantidad de sal en los alimentos procesados ha permitido que la hipertensión (HT) se instale hoy día como una pandemia. OBJETIVO: Revisar la bibliografía existente en el tema de adicción a la sal y sus consecuencias en la salud. MÉTODO: Se realizó una búsqueda en bases de datos PubMed, EBSCOhost y ScienceDirect con las palabras claves "salt", "salt addiction", "food addiction"; se revisaron los artículos que contuvieran información relativa al tema de interés así como referencias en estos mismos artículos e información histórica y cultural complementaria. RESULTADOS: Describimos la relación histórica entre el hombre y la sal, los mecanismos fisiológicos de percepción del sabor salado, su acción sobre el sistema de recompensa y las consecuencias en la salud de una dieta alta en sodio. DISCUSIÓN Y CONCLUSIÓN: Existe evidencia fisiológica y comportamental de que las personas pueden desarrollar una verdadera adicción a la ingestión de alimentos. Entre estas personas la adición a la sal juega un papel muy importante para el desarrollo de obesidad, hipertensión y otras enfermedades. El sodio está presente en altas cantidades en los alimentos procesados en forma de sal y glutamato monosódico (MSG), usados como conservadores o aditivos alimentarios, incluso en alimentos no salados como harinas y refrescos dulces.

Reward and aversion systems of the brain as a functional unit. Basic mechanisms and functions / Sistemas de recompensa y aversión del cerebro como una unidad funcional. Mecanismos básicos y funciones

INTRODUCTION: It is increasingly important to recognize the reward and aversion systems of the brain as a functional unit. A fundamental task of the mammalian brain is to assign an emotional/motivational valence to any stimuli by determining whether they are rewarding and should be approached or are aversive and should be avoided. Internal stimuli are also assigned an emotional/motivational valence in a similar fashion.OBJECTIVE: To understand the basic mechanisms and functions of the reward and aversion system of the brain.METHOD: A bibliographical search was conducted in the Pubmed database using different key words. Documents on relevant aspects of the topic were selected.RESULTS: In the ventral tegmental area, dopaminergic (VTA-DA) neurons play a role in reward-dependent behaviors. It is also known that the inhibition of the VTA-DA neurons by GABAergic neurons contributes to a reward prediction error calculation that promotes behaviors associated with aversion. The ventral dopaminergic mesolimbic system and the nucleus accumbens are activated during reward and inhibited during aversions. The amygdala is activated during aversive behavior.DISCUSSION AND CONCLUSION: The reward/aversion system is highly relevant for survival, which is most likely its primary function. It is involved in important pathologies such as addiction, depression and autonomic and endocrine disturbances. Therefore, its knowledge has become of clinical importance.Although great advances have been made in the knowledge of the basic mechanisms of the reward/aversion system, the detailed circuits within the VTA that mediate reward and aversion and the anatomical substrates are not completely clear.

INTRODUCCIÓN: Es muy importante reconocer el sistema de recompensa y aversión del cerebro como una unidad funcional. Una de las funciones fundamentales del cerebro de los mamíferos es la capacidad para designar un valor emocional/motivacional a cualquier estímulo. Esta capacidad permite identificar un estímulo como gratificante y aproximarnos a él, o reconocerlo como aversivo y evitarlo.OBJETIVO: Comprender los mecanismos fisiológicos del sistema de recompensa-aversión.MÉTODO: Se realizó una búsqueda bibliográfica en la base de datos Pubmed con las diferentes palabras clave. Se seleccionaron los documentos sobre los aspectos relevantes.RESULTADOS: Las neuronas dopaminérgicas del área tegmental ventral (ATV) cumplen un papel importante en los comportamientos dependientes de la recompensa. Asimismo, la inhibición de las neuronas dopaminérgicas ATV por parte de las neuronas GABAérgicas contribuye a predecir la recompensa y promueve comportamientos aversivos. Este sistema se activa durante actividades de recompensa y se inhibe durante la aversión. La amígdala es la principal estructura relacionada con la aversión.DISCUSIÓN Y CONCLUSIÓN: Este sistema se considera de gran importancia para la supervivencia de las especies, la que parece ser su función primordial. Interviene en distintas patologías como adicciones, depresión, trastorno por estrés postraumático, fobias y trastornos endocrinos y autonómicos, por lo que el conocimiento de este sistema es de gran importancia clínica.Aunque se ha avanzado mucho en el estudio y entendimiento de este sistema y de sus circuitos anatómicos ubicados en el ATV mesencefálica y sus conexiones con áreas subcorticales, el conocimiento de este sistema funcional sigue siendo un desafío científico.

Heart Rate and Systolic Blood Pressure Variability on Recently Diagnosed Diabetics / Variabilidade da Frequência Cardíaca e da Pressão Arterial Sistólica em Diabéticos com Diagnóstico Recente

Background:Diabetes affects approximately 250 million people in the world. Cardiovascular autonomic neuropathy is a common complication of diabetes that leads to severe postural hypotension, exercise intolerance, and increased incidence of silent myocardial infarction.Objective:To determine the variability of heart rate (HR) and systolic blood pressure (SBP) in recently diagnosed diabetic patients.Methods:The study included 30 patients with a diagnosis of type 2 diabetes of less than 2 years and 30 healthy controls. We used a Finapres® device to measure during five minutes beat-to-beat HR and blood pressure in three experimental conditions: supine position, standing position, and rhythmic breathing at 0.1 Hz. The results were analyzed in the time and frequency domains.Results:In the HR analysis, statistically significant differences were found in the time domain, specifically on short-term values such as standard deviation of NN intervals (SDNN), root mean square of successive differences (RMSSD), and number of pairs of successive NNs that differ by more than 50 ms (pNN50). In the BP analysis, there were no significant differences, but there was a sympathetic dominance in all three conditions. The baroreflex sensitivity (BRS) decreased in patients with early diabetes compared with healthy subjects during the standing maneuver.Conclusions:There is a decrease in HR variability in patients with early type 2 diabetes. No changes were observed in the BP analysis in the supine position, but there were changes in BRS with the standing maneuver, probably due to sympathetic hyperactivity.

Fundamento:O diabetes afeta aproximadamente 250 milhões de pessoas no mundo. A neuropatia autonômica cardiovascular é uma complicação comum do diabetes que leva à hipotensão postural grave, intolerância ao exercício e aumento na incidência de infarto do miocárdio silencioso.Objetivo:Determinar a variabilidade da frequência cardíaca (FC) e da pressão arterial sistólica (PAS) em pacientes diabéticos com diagnóstico recente.Métodos:O estudo incluiu 30 pacientes com diabetes tipo 2 diagnosticado há menos de 2 anos e 30 controles saudáveis. Nós utilizamos o dispositivo Finapres® para medir durante cinco minutos a FC batimento-a-batimento e a pressão arterial (PA) em três condições experimentais: posição supina, em pé e durante respiração rítmica na frequência de 0,1 Hz. Os resultados foram analisados nos domínios do tempo e da frequência.Resultados:Em relação à FC, foram encontradas diferenças estatisticamente significativas nos valores da análise do domínio do tempo, especificamente em valores determinados a curto prazo, tais como o desvio-padrão dos intervalos NN (DPNN), a raiz quadrada da média das diferenças sucessivas (RQMDS) para a FC e o número de pares de NNs sucessivos que diferem em mais de 50 ms (pNN50). Não houve diferença significativa na análise da PA, mas houve uma dominância simpática nas três condições. A sensibilidade do barorreflexo (SBR) esteve diminuída em pacientes com diabetes de início recente, em comparação aos indivíduos saudáveis durante execução da manobra na posição ortostática.Conclusões:Há uma diminuição na variabilidade da FC em pacientes com diabetes tipo 2 de início recente. Não foram observadas alterações na análise da PA na posição supina, mas a SBR apresentou mudança com a manobra em pé provavelmente causada por hiperatividade simpática.

Los barorreflejos arteriales cardiovagal, cardiosimpático y vasosimpático y el control neural de la presión arterial a corto plazo / The cardiovagal, cardiosympathetic and vasosympathetic arterial baroreflexes and the neural control of short-term blood pressure

Introducción. Los factores que modulan la presión arterial a corto plazo se encuentran puntualmente regulados para mantenerla dentro de valores de referencia. Esto se logra gracias a la existencia de mecanismos de autorregulación, tanto humorales como nerviosos. Los mecanismos neurogénicos son reflejos y su resultado se observa en cambios de presión arterial de forma inmediata, latido a latido. Desarrollo. Los reflejos nerviosos cardiovasculares se encuentran mediados por los barorreceptores arteriales, a través de los efectores cardiovagal, cardiosimpático y vasosimpático. El barorreceptor es estimulado cuando el volumen de sangre eyectado por el ventrículo distiende las paredes arteriales del seno carotídeo y la aorta proximal y estimula los mecanorreceptores situados en la adventicia de estos vasos. El estímulo aferente viaja hasta el núcleo del haz solitario en el bulbo raquídeo y otras áreas en el puente donde se integran estos reflejos y la parte eferente genera cambios compensatorios en la frecuencia cardíaca y el tono del músculo liso vascular. Esta modificación súbita es la responsable de la variabilidad de la presión arterial latido a latido (corto plazo). Conclusión. Se realiza una revisión sobre la historia, la fisiología y los experimentos de los barorreflejos cardiovagal, cardiosimpático y vasosimpático y su influencia en la variabilidad de la presión arterial a corto plazo (AU)

Introduction. The factors that control the blood pressure are punctually regulated to keep it in reference values. These are maintained through autoregulatory mechanisms, humoral, nervous and endothelial-related. The humoral mechanisms are complex and modify the long-term blood pressure, in the other hand, the neurogenic mechanisms, are reflexive and can be observed in beat-to-beat changes of blood pressure. Development. The nervous cardiovascular reflexes are mediated by high-pressure and low-pressure baroreceptors, as cardiovagal, cardiosympathetic and vasosympathetic. The arterial baroreceptor are stimulated when the blood volumeejected by the ventricle distend the arterial walls. The neural discharge travels to the autonomic centers in the brain stem and the result is the modification of the heart rate and the vascular smooth muscle tone. This sudden modification is the responsible of the beat-to-beat (short-term) blood pressure variability. Conclusion. A review was made on the history of the physiology and experiments of the cardiovagal, cardiosympathetic and vasosympathetic baroreflexes and its influence in the short-term blood pressure variability (AU)